{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:59:08Z","timestamp":1789520348602,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die chronische Hepatitis-C-Infektion kann unbehandelt zu schwerwiegenden und potenziell lebensbedrohlichen leberassoziierten Komplikationen f\u00fchren. Grunds\u00e4tzlich stellt damit jede chronische Infektion mit dem Hepatitis-C-Virus (HCV) eine Indikation zur antiviralen Therapie dar. Besonders dringlich ist sie jedoch bei Patient*innen mit fortgeschrittener Lebererkrankung. In diesem Beitrag werden Indikation, Therapieziele und Grundprinzipien der direkt antiviralen Therapie beschrieben. Verschiedene Therapieregime und M\u00f6glichkeiten der \u00dcberwachung von Therapie und Therapieerfolg werden vorgestellt.<\/jats:p><jats:p>Heutzutage wird die chronische HCV-Infektion interferonfrei mit direkt antiviral wirksamen Medikamenten (\u201edirect acting antivirals\u201c\u00a0\u2013 DAA) behandelt, wobei die Wahl der Medikamente von HCV-Genotyp, Vortherapie und Fibrosestatus abh\u00e4ngt. Patient*innen mit kompensierter Leberzirrhose und solche ohne Leberzirrhose weisen unter Behandlung vergleichbar hohe Viruseradikationsraten auf. Auch bei dekompensierter Leberzirrhose oder dialysepflichtiger Niereninsuffizienz und selbst bei Kindern ab einem Alter von 3\u00a0Jahren ist heutzutage eine sichere und hocheffiziente antivirale Behandlung m\u00f6glich. Medikamenteninteraktionen sind zu beachten, k\u00f6nnen aber einfach und schnell im Internet \u00fcberpr\u00fcft werden. Auch wenn sich die Prognose nach HCV-Eradikation deutlich verbessert, sollten Patient*innen mit fortgeschrittener Leberfibrose bzw. einer Leberzirrhose lebenslang weiterbeobachtet werden, um die Entstehung eines hepatozellul\u00e4ren Karzinoms rechtzeitig zu erkennen (HCC-Surveillance).<\/jats:p>","DOI":"10.1007\/s00103-021-03481-z","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T12:04:03Z","timestamp":1641816243000},"page":"246-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Behandlung von Hepatitis-C-Infektionen im Zeitalter direkt wirkender antiviraler Medikamente (DAAs)","Treatment of hepatitis\u00a0C infections in the era of direct-acting antivirals (DAAs)"],"prefix":"10.1007","volume":"65","author":[{"given":"Kai-Henrik","family":"Peiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"3481_CR1","volume-title":"Hepatitis C fact sheet","author":"WHO","year":"2021","unstructured":"WHO (2021) Hepatitis C fact sheet"},{"key":"3481_CR2","first-page":"1","volume":"28","author":"RKI","year":"2021","unstructured":"RKI (2021) Epidemiol Bull 28:1\u201322","journal-title":"Epidemiol Bull"},{"key":"3481_CR3","first-page":"11","volume":"114","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem\u00a0S (2017) Treatment options in hepatitis C. Dtsch Arztebl Int 114:11\u201321","journal-title":"Dtsch Arztebl Int"},{"key":"3481_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1055\/a-1226-1841","volume":"58","author":"C Sarrazin","year":"2020","unstructured":"Sarrazin\u00a0C, Zimmermann\u00a0T, Zeuzem\u00a0S (2020) Z\u00a0Gastroenterol 58:1107\u20131108","journal-title":"Z Gastroenterol"},{"key":"3481_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"Polaris Observatory HCVC","year":"2017","unstructured":"Polaris Observatory HCVC (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a\u00a0modelling study. Lancet Gastroenterol Hepatol 2:161\u2013176","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3481_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11904-017-0358-8","volume":"14","author":"M Martinello","year":"2017","unstructured":"Martinello\u00a0M, Hajarizadeh\u00a0B, Grebely\u00a0J, Dore\u00a0GJ, Matthews\u00a0GV (2017) HCV cure and reinfection among people with HIV\/HCV coinfection and people who inject drugs. Curr HIV\/AIDS Rep 14:110\u2013121","journal-title":"Curr HIV\/AIDS Rep"},{"key":"3481_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons\u00a0B, Saleem\u00a0J, Heath\u00a0K, Cooke\u00a0GS, Hill\u00a0A (2015) Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a\u00a0sustained virological response. Clin Infect Dis 61:730\u2013740","journal-title":"Clin Infect Dis"},{"key":"3481_CR8","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.jhep.2020.08.006","volume":"73","author":"V Calvaruso","year":"2020","unstructured":"Calvaruso\u00a0V, Craxi\u00a0A (2020) Hepatic benefits of HCV cure. J\u00a0Hepatol 73:1548\u20131556","journal-title":"J Hepatol"},{"key":"3481_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","volume":"155","author":"V Calvaruso","year":"2018","unstructured":"Calvaruso\u00a0V, Cabibbo\u00a0G, Cacciola\u00a0I, Petta\u00a0S, Madonia\u00a0S, Bellia\u00a0A et al (2018) Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 155:411\u2013421.e4","journal-title":"Gastroenterology"},{"key":"3481_CR10","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1055\/a-0598-5242","volume":"56","author":"T Zimmermann","year":"2018","unstructured":"Zimmermann\u00a0T, Jansen\u00a0PL, Sarrazin\u00a0C, Vollmar\u00a0J, Zeuzem\u00a0S (2018) Z\u00a0Gastroenterol 56:e53\u2013e115","journal-title":"Z Gastroenterol"},{"key":"3481_CR11","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson\u00a0IM, McHutchison\u00a0JG, Dusheiko\u00a0G, Di Bisceglie\u00a0AM, Reddy\u00a0KR, Bzowej\u00a0NH et\u00a0al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N\u00a0Engl J Med 364:2405\u20132416","journal-title":"N Engl J Med"},{"key":"3481_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad\u00a0F, McCone\u00a0J Jr., Bacon\u00a0BR, Bruno\u00a0S, Manns\u00a0MP, Sulkowski\u00a0MS et\u00a0al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N\u00a0Engl J Med 364:1195\u20131206","journal-title":"N Engl J Med"},{"key":"3481_CR13","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld\u00a0JJ, Jacobson\u00a0IM, Hezode\u00a0C, Asselah\u00a0T, Ruane\u00a0PJ, Gruener\u00a0N et\u00a0al (2015) Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N\u00a0Engl J Med 373:2599\u20132607","journal-title":"N Engl J Med"},{"key":"3481_CR14","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster\u00a0GR, Afdhal\u00a0N, Roberts\u00a0SK, Brau\u00a0N, Gane\u00a0EJ, Pianko\u00a0S et\u00a0al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N\u00a0Engl J Med 373:2608\u20132617","journal-title":"N Engl J Med"},{"key":"3481_CR15","unstructured":"Fachinformation: Epclusa\u00ae 400\u202fmg\/100\u202fmg Filmtabletten. Juli 2021"},{"key":"3481_CR16","unstructured":"Fachinformation: Maviret\u00ae 100\u202fmg\/40\u202fmg Filmtabletten. Juni 2021"},{"key":"3481_CR17","unstructured":"Fachinformation: Harvoni\u00ae 90\u202fmg\/400\u202fmg Filmtabletten. September 2021"},{"key":"3481_CR18","unstructured":"DGVS. Online-Vorabver\u00f6ffentlichung des Therapieteils im Rahmen Aktualisierung der S3-Leitlinie zur \u201eHepatitis-C-Virus (HCV)-Infektion; Prophylaxe, Diagnostik und Therapie\u201c. Dezember 2016"},{"key":"3481_CR19","unstructured":"Fachinformation: Zepatier\u00ae 50\u202fmg\/100\u202fmg Filmtabletten. November 2020"},{"key":"3481_CR20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.007","author":"J Dietz","year":"2017","unstructured":"Dietz\u00a0J, Susser\u00a0S, Vermehren\u00a0J, Peiffer\u00a0KH, Grammatikos\u00a0G, Berger\u00a0A et\u00a0al (2017) Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. https:\/\/doi.org\/10.1053\/j.gastro.2017.11.007","journal-title":"Gastroenterology"},{"key":"3481_CR21","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere\u00a0M, Gordon\u00a0SC, Flamm\u00a0SL, Cooper\u00a0CL, Ramji\u00a0A, Tong\u00a0M et\u00a0al (2017) Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection. N\u00a0Engl J Med 376:2134\u20132146","journal-title":"N Engl J Med"},{"key":"3481_CR22","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","volume":"71","author":"J Llaneras","year":"2019","unstructured":"Llaneras\u00a0J, Riveiro-Barciela\u00a0M, Lens\u00a0S, Diago\u00a0M, Cachero\u00a0A, Garcia-Samaniego\u00a0J et al (2019) Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J\u00a0Hepatol 71:666\u2013672","journal-title":"J Hepatol"},{"key":"3481_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","volume":"71","author":"E Degasperi","year":"2019","unstructured":"Degasperi\u00a0E, Spinetti\u00a0A, Lombardi\u00a0A, Landonio\u00a0S, Rossi\u00a0MC, Pasulo\u00a0L et al (2019) Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure. J\u00a0Hepatol 71:1106\u20131115","journal-title":"J Hepatol"},{"key":"3481_CR24","volume-title":"S3-Leitlinie \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion\u201c AWMF-Register-Nr.: 021\/012","author":"C Sarrazin","year":"2017","unstructured":"Sarrazin\u00a0C, Zimmerman\u00a0T, Berg\u00a0T, Neumann\u00a0U, Schirmacher\u00a0P, Schmitt\u00a0H et al (2017) S3-Leitlinie \u201eProphylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion\u201c AWMF-Register-Nr.: 021\/012"},{"key":"3481_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/hep.29135","volume":"66","author":"PS Belperio","year":"2017","unstructured":"Belperio\u00a0PS, Shahoumian\u00a0TA, Mole\u00a0LA, Backus\u00a0LI (2017) Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 66:27\u201336","journal-title":"Hepatology"},{"key":"3481_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","volume":"3","author":"MM Mucke","year":"2018","unstructured":"Mucke\u00a0MM, Backus\u00a0LI, Mucke\u00a0VT, Coppola\u00a0N, Preda\u00a0CM, Yeh\u00a0ML et al (2018) Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a\u00a0systematic review and meta-analysis. Lancet Gastroenterol Hepatol 3:172\u2013180","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3481_CR27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.30840","volume":"71","author":"MM Jonas","year":"2020","unstructured":"Jonas\u00a0MM, Squires\u00a0RH, Rhee\u00a0SM, Lin\u00a0CW, Bessho\u00a0K, Feiterna-Sperling\u00a0C et al (2020) Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 71:456\u2013462","journal-title":"Hepatology"},{"key":"3481_CR28","unstructured":"www.hep-druginteractions.org. Zugegriffen: 21.\u00a0Nov 2021"},{"key":"3481_CR29","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF) Diagnostik und Therapie des Hepatozellul\u00e4ren Karzinoms und bili\u00e4rer Karziome, Langversion 2.0, 2021, AWMF Registernummer: 032\/053OL. https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/hcc-und-billi\u00e4re-karzinome. Zugegriffen: 21.\u00a0Nov 2021"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-021-03481-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-021-03481-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T07:05:23Z","timestamp":1643871923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-021-03481-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["3481"],"URL":"https:\/\/doi.org\/10.1007\/s00103-021-03481-z","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"5 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.-H.\u00a0Peiffer war als Referent f\u00fcr die Biotechnologie- und Pharmaunternehmen Abbvie und Gilead Sciences t\u00e4tig. S.\u00a0Zeuzem war als Berater- u.\/o. Gutachter u.\/o. Referent f\u00fcr die Biotechnologie- und Pharmaunternehmen Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceutica und Merck Sharp & Dohme t\u00e4tig.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}